Financials data is unavailable for this security.
View more
Year on year JiangSu WuZhong Pharmaceutical Development Co Ltd grew revenues 10.55% from 2.03bn to 2.24bn while net income improved from a loss of 76.20m to a smaller loss of 71.95m.
| Gross margin | 24.38% |
|---|---|
| Net profit margin | -3.25% |
| Operating margin | -3.21% |
| Return on assets | -1.86% |
|---|---|
| Return on equity | -4.14% |
| Return on investment | -3.74% |
More ▼
Cash flow in CNYView more
In 2023, JiangSu WuZhong Pharmaceutical Development Co Ltd increased its cash reserves by 21.09%, or 278.94m. Cash Flow from Investing totalled 358.90m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 203.68m for operations while cash generated from financing totalled 123.85m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.49 |
|---|---|
| Tangible book value per share | 1.95 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.46 |
|---|---|
| Quick ratio | 1.41 |
| Total debt/total equity | 1.03 |
|---|---|
| Total debt/total capital | 0.4993 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 5.57%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -154.81 |
